MedTrace Logo

Study of PEP02 as a Second Line Therapy for Metastatic Pancreatic Cancer

NCT00813163 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2019-09-06

No results posted yet for this study

Summary

The purpose of this study is to see the effect of PEP02 in the treatment of metastatic pancreatic cancer.

Conditions

  • Pancreatic Neoplasms

Interventions

DRUG

PEP02

120 mg/m2, IV infusion for 90 minutes on day 1 of each 21 days as a treatment cycle. Number of Cycles: until progression or unacceptable toxicity develops.

Sponsors & Collaborators

  • PharmaEngine

    lead INDUSTRY

Principal Investigators

  • Li-Tzong Chen, M.D. · National Health Research Institutes, Taiwan

  • Andrew H Ko, M.D. · University of California, San Francisco

  • Yu-Lin Lin, M.D. · National Taiwan University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2010-12-31
Completion
2012-07-31

Countries

  • United States
  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00813163 on ClinicalTrials.gov